Genetic Studies of Actinic Keratosis Development: Where Are We Now?

被引:2
|
作者
Lee, Young Bok [1 ,2 ,3 ]
Kim, Jong-Il [3 ,4 ,5 ,6 ,7 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, Seoul, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Dermatol, Seoul, South Korea
[3] Seoul Natl Univ, Genom Med Inst GMI, Med Res Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea
[5] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea
[7] Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Actinic keratosis; Cutaneous squamous cell carcinoma; SQUAMOUS-CELL CARCINOMA; CHROMOSOMAL-ABERRATIONS; SKIN; MUTATIONS; CANCER; P53; P16(INK4A); EXPRESSION; PATTERNS; RISK;
D O I
10.5021/ad.23.072
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Actinic keratosis (AK) is a common precancerous skin lesion that can develop into cutaneous squamous cell carcinoma (CSCC). AK is characterized by atypical keratinocytes in the skin's outer layer and is commonly found in sun-exposed areas. Like many precancerous lesions, the development of AK is closely associated with genetic mutations. The molecular biology and transcriptional mechanisms underlying AK development are not well understood. Ultraviolet (UV) light exposure, especially UVA and UVB radiation, is a significant risk factor for AK, causing DNA damage and mutagenic effects. Besides UV exposure, comorbidities like diabetes, rheumatoid arthritis, and psoriasis may also influence AK development. AK patients have shown associations with various internal malignancies, indicating potential vulnerability in cancer-associated genes. Treatment for AK includes cryosurgery, electrodesiccation and curettage, chemotherapeutic creams, photodynamic therapy, or topical immune-modulators. Genomic studies have identified genetic aberrations in AK, with common mutations found in genes like TP53, NOTCH1, and NOTCH2. The progression from AK to CSCC involves chromosomal aberrations and alterations in oncogenes and tumor-suppressor genes. The functional relationships among these genes are not fully understood, but network analysis provides insights into their potential mechanisms. Further research is needed to enhance our understanding of AK's pathogenesis and develop novel therapeutic approaches.
引用
收藏
页码:389 / 399
页数:11
相关论文
共 50 条
  • [1] Actinic keratosis: where do we stand and where is the future going to take us?
    Cramer, Philipp
    Stockfleth, Eggert
    EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (01) : 49 - 58
  • [2] Genetic counseling globally: Where are we now?
    Ormond, Kelly E.
    Laurino, Mercy Ygona
    Barlow-Stewart, Kristine
    Wessels, Tina-Marie
    Macaulay, Shelley
    Austin, Jehannine
    Middleton, Anna
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2018, 178 (01) : 98 - 107
  • [3] Primary Aldosteronism: Where Are We Now? Where to from Here?
    Funder, John Watson
    HORMONE AND METABOLIC RESEARCH, 2020, 52 (06) : 459 - 466
  • [4] Risk of skin cancer development in 672 patients affected by actinic keratosis
    Dika, Emi
    Fanti, Pier A.
    Misciali, Cosimo
    Vaccari, Sabina
    Crisman, Giuliana
    Barisani, Alessia
    Baraldi, Carlotta
    Ribero, Simone
    Patrizi, Annalisa
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2016, 151 (06): : 628 - 633
  • [5] Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
    Fazio, Nicola
    Abdel-Rahman, Omar
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (03)
  • [6] Ergothioneine, where are we now?
    Halliwell, Barry
    Cheah, Irwin
    FEBS LETTERS, 2022, 596 (10) : 1227 - 1230
  • [7] Where are we now with paracetamol?
    Dear, James W.
    Antoine, Daniel J.
    Park, B. Kevin
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
  • [8] Biomarkers to detect Wilms tumors in pediatric patients: where are we now?
    Charlton, Jocelyn
    Pavasovic, Vesna
    Pritchard-Jones, Kathy
    FUTURE ONCOLOGY, 2015, 11 (15) : 2221 - 2234
  • [9] Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?
    Finn, Richard S.
    CLINICAL CANCER RESEARCH, 2010, 16 (02) : 390 - 397
  • [10] The pursuit of genome-wide association studies: where are we now?
    Chee Seng Ku
    En Yun Loy
    Yudi Pawitan
    Kee Seng Chia
    Journal of Human Genetics, 2010, 55 : 195 - 206